Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for TCER® IMA402 (PRAME) in Solid tumor/s, Cancer. The expected timing is based on the latest available company guidance and may change.
8/10/23: 11/12/25: Phase 1a data reported; Phase 1b dose expansion initiated. 11/17/25: Clinical proof-of-concept confirmed; Phase 1b expansion ongoing with additional cohorts planned in 2026. 03/05/26:- Final RP2D and larger Ph1b data update expected H2 2026; new Ph1b cohorts and IMA401 combo starting 2026. 05/12/26:- Ph1b IMA402 mono/checkpoint data and RP2D update expected H2 2026; new cohorts and IMA401 combo start mid-2026. 05/31/26:- IMA401/IMA402 sqNSCLC cohort enrolling; first combo data expected 2027. 07/17/26:- ESMO 2026 Phase 1b IMA402 results abstract Oct 19; rapid oral Oct 24, 2026. 08/18/26:- New Phase 1b cohorts opened. RP2D-range data will be presented at ESMO 2026.
Verification
Confirm timing and program details against the company announcement or filing.